Extrarenal vitamin D activation and interactions between vitamin D₂, vitamin D₃, and vitamin D analogs.

Our understanding of the mechanism of action of vitamin D has been broadened by the discovery of the extrarenal 1α-hydroxylase (CYP27B1) in various vitamin D target tissues around the body and the implications of this for the putative paracrine actions of 1α,25-dihydroxyvitamin D₃. This review updates our current knowledge of the cytochrome P450-mediated steps of vitamin D activation (CYP2R1, CYP27B1) and inactivation (CYP24A1, CYP3A4) and the newest physiological roles of vitamin D. The review goes on to examine how well exogenously supplied vitamin D compounds, whether dietary vitamin D₂ supplements or prescribed vitamin D analogs, substitute for their natural counterparts; how in some cases vitamin D can be used in conjunction with vitamin D analogs; and the overall impact of these supplements and drugs on the components of the vitamin D signal transduction machinery.

[1]  T. Travison,et al.  Serum concentrations of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation. , 2013, The Journal of clinical endocrinology and metabolism.

[2]  David W. Johnson,et al.  Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3–4: A randomized controlled trial , 2013, Nephrology.

[3]  Nutritional vitamin D use in chronic kidney disease: a survey of pediatric nephrologists , 2013, Pediatric Nephrology.

[4]  A. Luke,et al.  Mortality Rates Across 25-Hydroxyvitamin D (25[OH]D) Levels among Adults with and without Estimated Glomerular Filtration Rate <60 ml/min/1.73 m2: The Third National Health and Nutrition Examination Survey , 2012, PloS one.

[5]  T. Ziegler,et al.  High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. , 2012, The American journal of clinical nutrition.

[6]  H. DeLuca,et al.  Where is the vitamin D receptor? , 2012, Archives of biochemistry and biophysics.

[7]  N. Binkley.  Vitamin D and osteoporosis-related fracture. , 2012, Archives of biochemistry and biophysics.

[8]  H. DeLuca,et al.  Vitamin D 25-hydroxylase - Four decades of searching, are we there yet? , 2012, Archives of biochemistry and biophysics.

[9]  Glenville Jones,et al.  25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. , 2012, Archives of biochemistry and biophysics.

[10]  Elina Hyppönen,et al.  Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis , 2012, The American journal of clinical nutrition.

[11]  C. Gordon,et al.  Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. , 2012, The Journal of clinical endocrinology and metabolism.

[12]  Christine L. Taylor,et al.  IOM committee members respond to Endocrine Society vitamin D guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[13]  Lynette M. Smith,et al.  Dose Response to Vitamin D Supplementation in Postmenopausal Women , 2012, Annals of Internal Medicine.

[14]  Dawn S Milliner,et al.  Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. , 2012, The Journal of clinical endocrinology and metabolism.

[15]  G. Carter.  25-hydroxyvitamin D: a difficult analyte. , 2012, Clinical chemistry.

[16]  Glenville Jones.  Vitamin D analogs. , 2012, Rheumatic diseases clinics of North America.

[17]  Toshiko Tanaka,et al.  Genome-wide association study of circulating retinol levels , 2011, Human molecular genetics.

[18]  M. Konrad,et al.  Mutations in CYP24A1 and idiopathic infantile hypercalcemia. , 2011, The New England journal of medicine.

[19]  C. Sempos,et al.  Vitamin D status: United States, 2001-2006. , 2011, NCHS data brief.

[20]  S. Judd,et al.  Vitamin D Therapy and Cardiovascular Health , 2011, Current hypertension reports.

[21]  M. Drezner,et al.  Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. , 2011, The Journal of clinical endocrinology and metabolism.

[22]  J. Adams,et al.  Extrarenal 1α-Hydroxylase , 2011 .

[23]  C. Helvig,et al.  CYP24A1 Regulation in Health and Disease , 2011 .

[24]  M. Haussler,et al.  Nuclear vitamin D receptor: Natural ligands, molecular structure-function, and transcriptional control of vital genes , 2011 .

[25]  M. Holick.  Chapter 2 – Photobiology of Vitamin D , 2011 .

[26]  Christine L. Taylor,et al.  Dietary Reference Intakes for Calcium and Vitamin D , 2016, Pediatric Clinical Practice Guidelines & Policies.

[27]  Daniel L. Koller,et al.  Common genetic determinants of vitamin D insufficiency: a genome-wide association study , 2010, The Lancet.

[28]  C. Helvig,et al.  Vitamin D analogues targeting CYP24 in chronic kidney disease , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  Ravinder J. Singh,et al.  Comparison of Metabolism of Vitamins D2 and D3 in Children With Nutritional Rickets , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  Jason R. Stubbs,et al.  Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. , 2010, Journal of the American Society of Nephrology : JASN.

[31]  M. Holick,et al.  Photobiology of Vitamin D , 2010 .

[32]  P. Glendenning,et al.  Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. , 2009, Bone.

[33]  S. Libutti,et al.  Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. , 2009, American journal of physiology. Renal physiology.

[34]  S. Judd,et al.  Vitamin D Deficiency and Risk for Cardiovascular Disease , 2009, The American journal of the medical sciences.

[35]  K. Yasuda,et al.  Metabolism of 1alpha,25-dihydroxyvitamin D2 by human CYP24A1. , 2009, Biochemical and biophysical research communications.

[36]  P. Kiely,et al.  The tolerability and biochemical effects of high‐dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency , 2009, Scandinavian journal of rheumatology.

[37]  J. Strain,et al.  Estimation of the dietary requirement for vitamin D in healthy adults. , 2008, The American journal of clinical nutrition.

[38]  D. Mangelsdorf,et al.  Nuclear receptors of the enteric tract: guarding the frontier. , 2008, Nutrition reviews.

[39]  A. Scillitani,et al.  Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. , 2008, The Journal of clinical endocrinology and metabolism.

[40]  B. Hollis,et al.  25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. , 2008, The American journal of clinical nutrition.

[41]  M. Holick,et al.  Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. , 2008, The Journal of clinical endocrinology and metabolism.

[42]  C. Mathieu,et al.  Vitamin D and human health: lessons from vitamin D receptor null mice. , 2008, Endocrine reviews.

[43]  Hee-Won Park,et al.  Structural analysis of CYP2R1 in complex with vitamin D3. , 2007, Journal of molecular biology.

[44]  Sungtae Kim,et al.  Molecular Actions of 1,25‐Dihydroxyvitamin D3 on Genes Involved in Calcium Homeostasis , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  Glenville Jones,et al.  Contemporary Diagnosis and Treatment of Vitamin D–Related Disorders , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  N. Stern,et al.  25 hydroxy-vitamin D3-1α hydroxylase expression and activity in cultured human osteoblasts and their modulation by parathyroid hormone, estrogenic compounds and dihydrotestosterone , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[47]  Glenville Jones,et al.  Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1α,25-(OH)2D3-26,23-lactone , 2007, Proceedings of the National Academy of Sciences.

[48]  M. Holick.  Vitamin D deficiency. , 2007, The New England journal of medicine.

[49]  Z. Al-Aly,et al.  Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[50]  A. Fournier,et al.  Impact of calcium and vitamin D therapy on arterial and cardiac disease in young adults with childhood-onset end stage renal disease. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  S. Sprague,et al.  Impact of Ergocalciferol Treatment of Vitamin D Deficiency on Serum Parathyroid Hormone Concentrations in Chronic Kidney Disease , 2007, American Journal of Nephrology.

[52]  R. Vieth,et al.  The case against ergocalciferol (vitamin D2) as a vitamin supplement. , 2006, The American journal of clinical nutrition.

[53]  R. Mehta,et al.  Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs. , 2006, Anticancer research.

[54]  K. Wernecke,et al.  Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[55]  J. Adams,et al.  Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.

[56]  W. L. Nelson,et al.  Intestinal and Hepatic CYP3A4 Catalyze Hydroxylation of 1α,25-Dihydroxyvitamin D3: Implications for Drug-Induced Osteomalacia , 2006, Molecular Pharmacology.

[57]  J. Halpert,et al.  CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. , 2005, The Journal of clinical endocrinology and metabolism.

[58]  Glenville Jones,et al.  Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. , 2005, Endocrinology.

[59]  W. Stumpf.  Vitamin D sites and mechanisms of action: A histochemical perspective. Reflections on the utility of autoradiography and cytopharmacology for drug targeting , 1995, Histochemistry and Cell Biology.

[60]  M. Holick.  Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. , 2004, The American journal of clinical nutrition.

[61]  B. Hollis,et al.  Vitamin D2 is much less effective than vitamin D3 in humans. , 2004, The Journal of clinical endocrinology and metabolism.

[62]  D. Oliver,et al.  Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease , 2004, American Journal of Nephrology.

[63]  F. Hu,et al.  Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. , 2004, The American journal of clinical nutrition.

[64]  Jeffrey B. Cheng,et al.  Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[65]  John H. White.  Profiling 1,25-dihydroxyvitamin D3-regulated gene expression by microarray analysis , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[66]  B. Hollis,et al.  CYP3A4 is a Human Microsomal Vitamin D 25‐Hydroxylase , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[67]  J. Gallagher,et al.  Effect of Vitamins D2 and D3 Supplement Use on Serum 25OHD Concentration in Elderly Women in Summer and Winter , 2004, Calcified Tissue International.

[68]  K. Miyamoto,et al.  Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 Production* , 2003, The Journal of Biological Chemistry.

[69]  M. Haussler,et al.  Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. , 2002, Biochemical and biophysical research communications.

[70]  W. Grant,et al.  Evidence supporting the role of vitamin D in reducing the risk of cancer , 2002, Journal of internal medicine.

[71]  E. Schuetz,et al.  Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. , 2001, Molecular pharmacology.

[72]  John H. White,et al.  Regulation of Gene Expression by 1α,25-Dihydroxyvitamin D3 and Its Analog EB1089 under Growth-Inhibitory Conditions in Squamous Carcinoma Cells , 2001 .

[73]  Olivier Dardenne,et al.  Targeted Inactivation of the 25-Hydroxyvitamin D3-1α-Hydroxylase Gene (CYP27B1) Creates an Animal Model of Pseudovitamin D-Deficiency Rickets. , 2001, Endocrinology.

[74]  M. Tremblay,et al.  Targeted ablation of the 25-hydroxyvitamin D 1α-hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[75]  A. Howie,et al.  Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1 , 2001 .

[76]  E. Slatopolsky,et al.  Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. , 2000, Journal of the American Society of Nephrology : JASN.

[77]  R. St-Arnaud,et al.  Targeted inactivation of vitamin D hydroxylases in mice. , 1999, Bone.

[78]  R. Vieth,et al.  Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. , 1998, The American journal of clinical nutrition.

[79]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[80]  F. Glorieux,et al.  The 25‐Hydroxyvitamin D 1‐Alpha‐Hydroxylase Gene Maps to the Pseudovitamin D‐Deficiency Rickets (PDDR) Disease Locus , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[81]  S. Kato,et al.  25-Hydroxyvitamin D3 1α-Hydroxylase and Vitamin D Synthesis , 1997 .

[82]  Tatsuya Yoshizawa,et al.  Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning , 1997, Nature Genetics.

[83]  R. Saracho,et al.  A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[84]  H. DeLuca,et al.  Effects of increasing doses of 1α‐hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women , 1994 .

[85]  Keiichi,et al.  Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene. , 1994, The Journal of biological chemistry.

[86]  G. Jones,et al.  Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Pike,et al.  Positive regulation of the vitamin D receptor by its cognate ligand in heterologous expression systems. , 1993, Molecular endocrinology.

[88]  J. Pike,et al.  Vitamin D3 receptors: structure and function in transcription. , 1991, Annual review of nutrition.

[89]  J. Delmez,et al.  Extrarenal production of calcitriol in normal and uremic humans. , 1991, The Journal of clinical endocrinology and metabolism.

[90]  R. Ray,et al.  Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. , 1989, The Biochemical journal.

[91]  C. Christiansen,et al.  Metabolism of vitamin D2 and vitamin D3 in patients on anticonvulsant therapy , 1989, Acta neurologica Scandinavica.

[92]  Reddy Gs,et al.  Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through the C-24 oxidation pathway , 1989 .

[93]  T. Clemens,et al.  Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. , 1986, The Journal of clinical endocrinology and metabolism.

[94]  C. Christiansen,et al.  Different metabolism of vitamin D2/D3 in epileptic patients treated with phenobarbitone/phenytoin. , 1986, Bone.

[95]  J. Adams,et al.  Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. , 1985, The Journal of clinical endocrinology and metabolism.

[96]  A. Norman,et al.  Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. , 1981, The New England journal of medicine.

[97]  H. DeLuca,et al.  Plasma concentrations of vitamin D3 and its metabolites in the rat as influenced by vitamin D3 or 25-hydroxyvitamin D3 intakes. , 1980, Archives of biochemistry and biophysics.

[98]  F. Glorieux,et al.  Simultaneous measurement of serum 25-hydroxycholecalciferol and 25-hydroxyergocalciferol. , 1979, Medical biology.

[99]  H. DeLuca.  Vitamin D: the vitamin and the hormone. , 1974, Federation proceedings.

[100]  H. DeLuca,et al.  Pathogenesis of Hereditary Vitamin-D-Dependent Rickets , 1973 .

[101]  H. DeLuca,et al.  The regulation of rat liver calciferol-25-hydroxylase. , 1973, The Journal of biological chemistry.

[102]  H. DeLuca,et al.  Isolation and identification of 24,25-dihydroxycholecalciferol, a metabolite of vitamin D made in the kidney. , 1972, Biochemistry.

[103]  R. J. Walsh,et al.  A comparison of the toxicity of ergocalciferol and cholecalciferol in rhesus monkeys (Macaca mulatta). , 1972, The Journal of nutrition.

[104]  D. Fraser,et al.  Unique Biosynthesis by Kidney of a Biologically Active Vitamin D Metabolite , 1970, Nature.

[105]  J. R. Roborgh,et al.  The hypercalcemic activity of dihydrotachysterol-2 and dihydrotachysterol-3 and of the vitamins D2 and D3 after intravenous injection of the aqueous preparations. 2. Comparative experiments on rats. , 1960, Biochemical pharmacology.

[106]  J. R. Roborgh,et al.  The hypercalcemic activity of dihydrotachysterol2 and dihydrotachysterol3 and of the vitamins D2 and D3: Comparative experiments on rats , 1959 .

[107]  E. A. Park.  THE THERAPY OF RICKETS , 1940 .